Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vonsetamig, an antibody targeting BCMA × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Acrixolimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zovostotug, an antibody targeting CD163.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nezutatug, an antibody targeting HER3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Polzastobart, an antibody targeting LILRB2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Puxitatug, an antibody targeting VTCN1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Davutamig, an antibody targeting MET.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Firastotug, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Erzotabart, an antibody targeting ADPRC1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vilastobart, an antibody targeting CTLA-4.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Zubotamig, an antibody targeting VTCN1 × CD3E.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Vislarafusp, an antibody targeting SIRPA.